<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089645</url>
  </required_header>
  <id_info>
    <org_study_id>D6840C00001</org_study_id>
    <nct_id>NCT03089645</nct_id>
  </id_info>
  <brief_title>MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.</brief_title>
  <official_title>A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone or in Combination With Durvalumab, Tremelimumab, and/or Docetaxel in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of
      Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult
      subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global Phase 1, first-time-in-human, multicenter, dose-escalation and
      dose-expansion study of MEDI5083 alone or in combination with Durvalumab, Tremelimumab,
      and/or Docetaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Actual">June 23, 2020</completion_date>
  <primary_completion_date type="Actual">June 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs) as a measure of safety</measure>
    <time_frame>From the time of consent through 120 days after last treatment</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>From the time of consent through 120 days after last treatment</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLTs) as a measure of safety</measure>
    <time_frame>From the time of first dose through 28 days thereafter</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Tolerated Dose (MTD) or Highest Protocol-Defined Dose</measure>
    <time_frame>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuation of investigational products due to toxicity</measure>
    <time_frame>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant alterations in vital signs, laboratory parameters, physical examination, and electrocardiogram (ECG) results.</measure>
    <time_frame>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity endpoints OR, based on RECIST v1.1</measure>
    <time_frame>Part 3</time_frame>
    <description>Safety Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum MEDI5083 concentration levels</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Pharmacokinetics (PK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in peripheral blood CD19+ B cells</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Pharmacodynamics (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) responses to MEDI5083</measure>
    <time_frame>From the time of first dose through 2 years after last treatment</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) at 6 months (PFS-6)</measure>
    <time_frame>From the time of first dose until 6 months after the last subject is dosed</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Durvalumab concentration levels collected over time</measure>
    <time_frame>From the time of first dose through 29 days after first treatment</time_frame>
    <description>Pharmacokinetics (PK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) responses to Durvalumab</measure>
    <time_frame>From the time of first dose through 2 years after last treatment</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) responses to tremelilumab</measure>
    <time_frame>From the time of first dose through 2 years after last treatment</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum tremelimumab concentration levels collected over time</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Pharmacodynamics (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD of MEDI5083 alone and in combination with Durvalumab and tremelimumab</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Pharmacodynamics (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of MEDI5083 with durvalumamb and docetaxel and in subjects with IO relapsed/refractory 2/3L NSCLC</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI5083 monotherapy</intervention_name>
    <description>Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEID5083 with Durvalumab or Tremelimumab</intervention_name>
    <description>Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medi5083 with Durvalumab and Docetaxel</intervention_name>
    <description>Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel</description>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years at the time of screening or age of consent according to local law

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          3. Histologically or cytologically confirmed metastatic or recurrent tumor types

          4. Subjects who have received prior immunotherapy may be eligible

          5. Subjects must have at least one measurable lesion

          6. Consent to provide archival tumor tissue and pre/on-treatment biopsies

          7. Adequate organ and marrow function

          8. Consent to use one highly effective method of contraception

        Exclusion Criteria:

          1. Receipt of any systemic anticancer therapy within 28 days prior to the first dose of
             MEDI5083

          2. Concurrent enrollment in another clinical study

          3. Active/prior autoimmune of inflammatory disorders

          4. History of immunodeficiency, solid organ transplant, or tuberculosis

          5. Known allergy/hypersensitivity to drug or components

          6. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or
             cord compression

          7. Current or prior use of immunosuppressive medication within 14 days prior to the first
             dose of MEDI5083
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>101 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune LLC</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-2191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

